Peptides for Diabetes Management
Comprehensive guide to 2 peptides researched for diabetes management, ranked by evidence strength from FDA-approved to early preclinical. Each compound is evaluated on mechanism, clinical status, and safety profile.
Overview
2 research peptides are currently studied for diabetes management. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Glucagon — FDA Approved
Evidence Rating: A
Category: Metabolic / Pancreatic Hormone
Glucagon is a 29-amino-acid peptide hormone (MW ~3482.8 g/mol) produced by pancreatic alpha cells that serves as the primary counter-regulatory hormone to insulin. Multiple formulations are available: traditional reconstituted injection (GlucaGen), intranasal powder (Baqsimi, approved 2019), and ready-to-use auto-injector (Gvoke, approved 2019), representing significant advances in emergency usability.
Key claims: Rapidly reverses severe hypoglycemia; Intranasal formulation is effective and easy to administer.
GLP-1 — Endogenous hormone with multiple approved analogs
Evidence Rating: A
Category: Metabolic / Weight Loss
GLP-1 (Glucagon-Like Peptide-1) is a 30-amino acid incretin hormone secreted by intestinal L-cells in response to food intake. It is the endogenous peptide behind the revolutionary class of GLP-1 receptor agonist drugs including semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and liraglutide (Saxenda). Native GLP-1 has a half-life of only 2-3 minutes due to rapid degradation by DPP-4 enzymes. All approved GLP-1 receptor agonist drugs are engineered analogs with extended half-lives. GLP-1-based therapies represent one of the most significant therapeutic advances in diabetes and obesity treatment in decades.
Key claims: Glucose-dependent insulin secretion; Significant weight loss via receptor agonists.
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Hanmi's Korea-made GLP-1 Eppe to challenge Wegovy, Mounjaro on price
Hanmi Pharmaceutical is preparing to launch Eppe, a Korea-developed GLP-1 drug, aiming to compete directly with Novo Nordisk's Wegovy and Eli Lilly's Mounjaro. The company plans to undercut rivals on price, potentially reshaping the obesity treatment market. Eppe's domestic production could offer cost advantages.
Wegovy News: Oral GLP-1 Tracker Shows Market Share Ceiling for Novo's Pill
Recent Wegovy news suggests Novo Nordisk's oral GLP-1 pill is struggling to break through a market share ceiling, according to industry reports. This analysis explores the implications for peptide researchers and the broader GLP-1 landscape.
Meant Launches LegitScript-Certified GLP-1 Telehealth Platform with Coaching
Meant has introduced a new telehealth platform for GLP-1 therapies that has earned LegitScript certification. The platform combines medical oversight with personalized coaching to support patients using GLP-1 medications. This launch marks a step forward in integrating digital health services with weight management treatments.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe